Biotech Rising

In 2014, the top six best-selling drugs will be biotech products, says EvaluatePharma, a healthcare analysis company. Of the top 100, they say biotech drugs will account for half. Evaulate predicts that the number one drug in five years will be Roche's Avastin, followed by Abbott's Humira, Roche's Rituxan, Wyeth's Enbrel, Sanofi-Aventis' Lantus, and Roche's Herceptin, according to Reuters.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.